California biotech Acelyrin has filed to go public, a rare attempt to access the stock markets after a year of stock declines and cutbacks across the industry. Acelyrin was founded by veterans of Horizon Therapeutics in 2020, and in-licenses drugs or acquires their owners, then funds their development. The startup raised a $300 million Series C last fall, on top of a $250 million Series B in 2021. It was valued at $800 million after the latest round, according to PitchBook.
Read the full article: Acelyrin Files to Go Public in Rare Sign of Biotech IPO //
Source: https://endpts.com/acelyrin-files-to-go-public-in-rare-sign-of-biotech-ipo